• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

连续性静脉-静脉血液滤过对庆大霉素和万古霉素的清除作用

Gentamicin and vancomycin removal by continuous venovenous hemofiltration.

作者信息

Thomson A H, Grant A C, Rodger R S, Hughes R L

机构信息

Department of Medicine and Therapeutics, Stobhill General Hospital, Glasgow, Scotland.

出版信息

DICP. 1991 Feb;25(2):127-9. doi: 10.1177/106002809102500203.

DOI:10.1177/106002809102500203
PMID:2058183
Abstract

The dispositions and dose requirements for vancomycin and gentamicin were investigated in a 58-year-old man who was receiving long-term continuous venovenous hemofiltration. Estimates of clearance were obtained using a Bayesian parameter estimation program and stayed remarkably consistent throughout the therapy. Single daily doses of both vancomycin and gentamicin generally maintained the profiles for both drugs around the target ranges of peak 5-10 mg/L (gentamicin) and 25-40 mg/L (vancomycin) and trough less than 2 mg/L (gentamicin) and less than 10 mg/L (vancomycin).

摘要

对一名正在接受长期持续静脉-静脉血液滤过的58岁男性患者的万古霉素和庆大霉素的处置情况及剂量需求进行了研究。使用贝叶斯参数估计程序获得清除率估计值,并且在整个治疗过程中保持显著一致。万古霉素和庆大霉素的每日单次剂量通常使两种药物的血药浓度维持在目标范围左右,即庆大霉素峰值为5-10mg/L、万古霉素峰值为25-40mg/L,庆大霉素谷值低于2mg/L、万古霉素谷值低于10mg/L。

相似文献

1
Gentamicin and vancomycin removal by continuous venovenous hemofiltration.连续性静脉-静脉血液滤过对庆大霉素和万古霉素的清除作用
DICP. 1991 Feb;25(2):127-9. doi: 10.1177/106002809102500203.
2
Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.持续静静脉血液滤过和持续静静脉血液透析对万古霉素清除率的影响因素。
Am J Kidney Dis. 1998 Jun;31(6):1019-27. doi: 10.1053/ajkd.1998.v31.pm9631848.
3
Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.危重症患者持续静静脉血液滤过期间的万古霉素清除率
Intensive Care Med. 1999 Oct;25(10):1100-4. doi: 10.1007/s001340051018.
4
Pharmacokinetics and administration method of gentamicin in a patient on haemodialysis.
Scand J Infect Dis. 2012 Aug;44(8):630-4. doi: 10.3109/00365548.2012.655774. Epub 2012 Feb 19.
5
Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.用于治疗金黄色葡萄球菌菌血症和心内膜炎的初始低剂量庆大霉素具有肾毒性。
Clin Infect Dis. 2009 Mar 15;48(6):713-21. doi: 10.1086/597031.
6
Evaluation of six gentamicin nomograms using a bayesian parameter estimation program.使用贝叶斯参数估计程序对六种庆大霉素列线图进行评估。
Ther Drug Monit. 1990 May;12(3):258-63. doi: 10.1097/00007691-199005000-00008.
7
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.美罗培南在接受持续静静脉血液滤过的急性肾衰竭重症患者中的药代动力学
Clin Pharmacol Ther. 1999 Jan;65(1):50-7. doi: 10.1016/S0009-9236(99)70121-9.
8
Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients.
J Chemother. 2012 Apr;24(2):107-12. doi: 10.1179/1120009X12Z.0000000006.
9
Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis.庆大霉素可能对葡萄球菌人工瓣膜心内膜炎的死亡率没有影响。
J Infect Chemother. 2018 Jul;24(7):555-562. doi: 10.1016/j.jiac.2018.03.003. Epub 2018 Apr 6.
10
Vancomycin clearance in high-volume venovenous hemofiltration.大剂量静脉-静脉血液滤过清除万古霉素。
Ann Pharmacother. 2013 Mar;47(3):e14. doi: 10.1345/aph.1Q488. Epub 2013 Feb 12.

引用本文的文献

1
Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.三级药物信息参考文献中持续肾脏替代疗法药物剂量推荐的存在情况与准确性。
Can J Hosp Pharm. 2012 May;65(3):188-95. doi: 10.4212/cjhp.v65i3.1141.
2
Clinical pharmacokinetics during continuous haemofiltration.持续血液滤过期间的临床药代动力学
Clin Pharmacokinet. 1994 Jun;26(6):457-71. doi: 10.2165/00003088-199426060-00004.
3
Bayesian parameter estimation and population pharmacokinetics.
Clin Pharmacokinet. 1992 Jun;22(6):447-67. doi: 10.2165/00003088-199222060-00004.